Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
AGIO · Nasdaq · United States · Pharmaceutical Preparations
In shortAGIOS PHARMACEUTICALS, INC. is loss-making.
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -873.9% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -764.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -30.2% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 11.46× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 12.52 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -698.3% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 3 | 100/100 |
| Revenue growth volatility | 27.4% | 10/100 |
| Operating margin volatility | 818.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 56.0% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 0 | 14 | 27 | 36 | 54 |
| Cost of revenue | 0 | 1.7 | 2.9 | 4.2 | 6.3 |
| Gross profit | 0 | 13 | 24 | 32 | 48 |
| Research & development | 257 | 280 | 296 | 301 | 340 |
| Selling, general & admin | 121 | 122 | 120 | 157 | 180 |
| Operating income | (378) | (389) | (391) | (426) | (472) |
| Pre-tax income | (357) | (232) | (352) | 718 | (414) |
| Income tax | – | 0 | 0 | 44 | (1) |
| Net income | 1,605 | (232) | (352) | 674 | (413) |
| Diluted EPS | $26.55 | −$4.23 | −$6.33 | $11.64 | −$7.12 |
| Diluted shares (millions) | 60 | 55 | 56 | 58 | 58 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
12.52 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 30, 2026